Table 1 Baseline information for the clinical trial population
Placebo (N = 12) | MgSO4 (N = 14) | |
|---|---|---|
Demographic and clinical features | ||
Age (months) | 21 (7, 57) | 24 (9, 73) |
Sex (female) | 6 (50) | 9 (64) |
Weight (kg) | 11 (7, 19) | 11 (7, 20) |
Illness day at enrolment | 3.5 (1.0, 6.0) | 3.0 (2.0, 5.0) |
Fever (> 37.5 °C) | 12 (100) | 13 (93) |
Mouth ulcers present | 10 (83) | 11 (79) |
Skin lesions present | 9 (75) | 11 (79) |
Skin ANS featuresa | 2 (17) | 1 (7) |
Tachycardiab | 2 (17) | 1 (7) |
SBP (mmHg) | 116 (105, 129) | 113 (101, 134) |
DBP (mmHg) | 61 (52, 73) | 59 (47, 73) |
Stage of hypertension | ||
Stage1 | 4 (33) | 11 (79) |
Stage2 | 8 (67) | 3 (21) |
Tachypnea | 5 (42) | 6 (43) |
Irregular breathing | 7 (58) | 5 (36) |
Respiratory retractions | 1 (8) | 3 (21) |
Irritability | 4 (33) | 1 (7) |
Neurological abnormalitiesc | 3 (25) | 0 (0) |
Laboratory investigations | ||
Arterial blood gases | ||
- pH | 7.44 (7.40, 7.59) | 7.41 (7.36, 7.48) |
- pCO2 (mmHg) | 29.8 (18.6, 35.7) | 33.3 (29.4, 40.1) |
Hb (g/dl) | 11.8 (8.8, 15.2) | 11.8 (6.4, 14.3) |
WBC (× 109/l) | 10.2 (4.6, 15.5) | 13.6 (5.5, 26.5) |
CK-MB (IU/l) | 23.4 (10.4, 64.8) | 25.4 (13.8, 48.1) |
Troponin I (pg/ml) | 5 (0, 20) | 5 (0, 27) |
Mg (mmol/l) | 0.85 (0.70, 0.99) | 0.88 (0.78, 0.98) |
Ca (mmol/l) | 2.28 (1.69, 2.52) | 2.31 (1.95, 2.42) |
Na (mmol/l) | 131 (126, 134) | 131 (125, 136) |
Creatinine (μmol/l) | 26 (17, 52) | 27 (18, 42) |
Blood sugar (mmol/l) | 5.4 (4.0, 7.6) | 5.7 (5.0, 8.1) |
Lab-confirmed EV infection | 7 (58) | 11 (78) |
EV-A71 positive | 4 (33) | 9 (64) |
Other EV positived | 3 (25) | 2 (14) |